HAI-ROBOTICS
24.3.2022 13:59:10 CET | Business Wire | Press release
HAI ROBOTICS will display its Autonomous Case-handling Robot (ACR) systems in Europe at the upcoming Transport and Logistics Innovation Week (SITL) 2022 in Paris from Apr. 5-8, an event it sees as the launchpad into more European countries.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220324005462/en/
SITL 2022 will also mark the debut of the company's local European team.
Considered a disruptive innovator, HAI ROBOTICS is committed to spearheading the future of warehouse automation, with a flexible, easily deployable and cost-effective solution that will massively increase supply chain efficiency in Europe.
Local Presence
Since setting up its regional headquarters in the Netherlands in late 2021, HAI ROBOTICS has expanded its presence quickly into several countries, such as France, Germany, Spain, Italy, the Benelux and the U.K.
It has quickly set up a local team, most of whom are industrial veterans.
Peter Guan, HAI ROBOTICS European General Manager, said HAI Robotics "is dedicated to hiring local top talent in each of the European key regions."
"The company has already employed the services of several native country managers with proven track records in the logistics automation industry. We keep searching for more local talent that can increase the level of our service and support," Mr Guan said.
"We are gearing up to do more exhibitions in Europe," he added.
An expert in building up, structuring and swiftly growing the European business of international companies that want to break into the market, Mr Guan used to be the sales & marketing director at Hikvision for more than ten years.
At SITL 2022, Mr Guan will be joined by Kai Ramadhin, VP of Sales & Marketing Europe, and Thierry Hennebiq, Country Manager France. Both were newly joined.
With more than 20 years of experience in the logistics market, Mr Ramadhin had previously worked with the Dutch corporation Van Riet Material Handling Systems as both interim CEO and the Director of Sales and Marketing.
With more than 10 years of experience in the intralogistics industry, Mr Hennebiq had previously fulfilled roles at the top system integrators in this industry including TGW, Dematic and Vanderlande.
The Better Fit
Compared with existing, especially traditional, warehouse automation solutions, HAI ROBOTICS believe its ACR systems are a better fit for European customers.
Take France, where SITL 2022 convenes, for example. Mr Hennebiq said "huge demand is observed," given the growing demand for logistic services.
"We think our ACR solution can give logistic service suppliers everything they need to optimize their warehouses for massively increased throughput and efficiency," he said.
Mr Ramadhin said HAI ROBOTICS' target industries include mainly 3PL, retail & e-commerce, fashion and FMCG. "Our ACR solution is catered to handle products in these markets."
Compared to logistic service suppliers employing a traditional human labor force, Mr Ramadhin said the ACR systems can "exponentially increase operational efficiency," whilst requiring less time to implement and being more cost-effective than traditional automation solutions.
"HAI ROBOTICS solution provides more flexibility in term of expansion ability, rapid deployment times and so on. So the sweet-spot of our solution is much more attractive," he said.
Mr Ramadhin noted the company is focused on creating a local network of system integrator, installation and service partners, so that any user of ACR systems can expect rapid and high-quality service wherever they are in Europe.
Since its foray into Europe last year, HAI ROBOTICS' presence has been expanding swiftly in the local warehousing logistics sector.
It has paired up with France-based global logistics solutions engineering company Savoye and has inked a strategic partnership with Greece's market leader in intralogistics Voyatzoglou Systems.
At a time when e-commerce booms, the company's ACR solution was deployed at a Micro-Fulfillment Center in Europe, significantly improving the last-mile delivery.
"We aim to provide our customers with high quality service and support, both through our own regional teams, as well as our robust network of installation and service partners," Mr Ramadhin said.
To see HAI ROBOTICS's ACR systems live, please visit booth K81, Paris - Nord Villepinte - Hall 6, during SITL 2022.
ABOUT HAI ROBOTICS
HAI ROBOTICS, the pioneer in Autonomous Case-handling Robot (ACR) systems, is committed to providing efficient, intelligent, flexible, and customized warehouse automation solutions through robotics technology and AI algorithms. It aims to create value for each factory and logistics warehouse. The HAIPICK ACR system, independently developed in 2015, is the world's first of its kind.
Founded in 2016 in Shenzhen, China, HAI ROBOTICS has offices in the U.S., Europe, Japan, Southeast Asia, Hong Kong and Taiwan, serving customers from more than 30 countries and regions.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220324005462/en/
Link:
Social Media:
https://www.facebook.com/HAIROBOTICS/videos/?ref=page_internal
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
